PaulChief Executive Officer and Founder
Paul Bilars was trained in Law and Public Administration at Leiden University, after which he worked in commercial and managerial roles at TNT. Later, he was hired by LUMC as an independent consultant in logistics and strategic sourcing, and managed to ensure business alignment and reduce costs with €20 million per annum. In 2011, Paul was appointed as managing director of LUMC’s largest division (budget >€140 million per annum and >1400fte). In this capacity, he is also responsible for valorization of IP. Furthermore, Paul was appointed managing director of Cardiology Centrum Voorschoten in, where he was able to restore revenue growth. In 2013, he founded a contract research unit within the LUMC. Paul currently also acts as board member of the Meteor Foundation and board member of the supervisory board of ‘Behandeladviescentrum Ouderengeneeskunde’.
PieterChief Scientific Officer and Founder
Emeritus professor Pieter Reitsma is a leading expert in coagulation and previous head of the department of Thrombosis and Hemostasis at LUMC. Pieter Reitsma has always worked at the interface of fundamental science and clinical applications. He is a translational scientist ‘avant la lettre’ who is among the very few to have brought drugs and diagnostic tests to the clinic. In the early stage of his career he did the experimental animal and in vitro work which was needed to bring the bisphosphonate APD to the clinic to successfully treat patients with destructive bone disease. Later he turned to the field of Hemostasis and Thrombosis where he made seminal contributions that made him world leader in the genetics of Hemostasis and Thrombosis. The test for factor V Leiden that he co-discovered is considered to be the most commonly performed genetic test in the world.
MaartjeChief Operating Officer
Maartje brings approximately 15 years of experience in the development of biologic therapeutics. She previously held R&D positions at AbbVie (US) and Abbott (the Netherlands), as well as at Crucell NV in the Netherlands, leading process development and manufacturing efforts. Maartje’s experience includes pre-clinical development up to and including Phase III/ commercial launch, including the preparation of regulatory filings from initial IND/IMPDs to BLA/MAA. Maartje is Senior Consultant at Venn Life Sciences, where she provides strategic, tactical and operational input to emerging and established biopharma. Maartje has a Msc. in Biotechnology from the University of Wageningen and a Ph.D. from Leiden University.